DeepMed Research

Bergenbio ASA

🇳🇴Norway

Country: 🇳🇴Norway

Ownership: Public

Established: 2007-01-01

Employees: 16

Market Cap: -

Website: http://www.bergenbio.com

Clinical Trials

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Myelodysplastic Syndromes
Metastatic Pancreatic Cancer
Glioblastoma
Malignant Mesothelioma
COVID-19
Metastatic Melanoma
Acute Myeloid Leukemia

Interventions: Drug: Bemcentinib

First Posted Date: 2024-06-21

Last Posted Date: 2025-01-29

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 6

Registration Number: NCT06469138

Locations: 🇬🇧
Labcorp Clinical Research Unit Ltd., Leeds, United Kingdom

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Bemcentinib
Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2022-07-21

Last Posted Date: 2025-05-09

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 26

Registration Number: NCT05469178

Locations: 🇭🇺
Fejer County St. Gyorgy Hospital, Szekesfehervar, Hungary
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇪🇸
MD Anderson Cancer Center, Oncology service, Madrid, Spain

and more 31 locations

A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Phase 1

Terminated

Conditions: Ovarian Neoplasms

Interventions: Biological: Tilvestamab

First Posted Date: 2021-05-19

Last Posted Date: 2023-04-20

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 16

Registration Number: NCT04893551

Locations: 🇸🇬
National University Hospital, Singapore, Singapore
🇳🇴
Haukeland University Hospital Bergen, Bergen, Norway
🇰🇷
Yonsei University Health System- Severance Hospital, Seoul, Korea, Republic of

and more 6 locations

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Bemcentinib
Other: SoC

First Posted Date: 2021-05-18

Last Posted Date: 2024-10-16

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 115

Registration Number: NCT04890509

Locations: 🇮🇳
Unity Trauma Center and ICU, Unity Hospital, Surat, Gujarat, India
🇿🇦
Lakeview Hospital, Mowbray, Benoni, South Africa
🇮🇳
Kasturba Medical College, Mangalore, Karnataka, India

and more 9 locations

A First-time-in-human Study of BGB149

Early Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: Placebo
Biological: BGB149

First Posted Date: 2019-01-07

Last Posted Date: 2022-03-16

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 24

Registration Number: NCT03795142

Locations: 🇬🇧
Parexel Northwick Park, London, Harrow, Middlesex, United Kingdom

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Phase 2

Completed

Conditions: Lung Cancer Metastatic
NSCLC Stage IV
Adenocarcinoma of Lung

Interventions: Drug: Bemcentinib; pembrolizumab

First Posted Date: 2017-06-12

Last Posted Date: 2023-10-10

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 106

Registration Number: NCT03184571

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center (DHMC), Lebanon, New Hampshire, United States
🇳🇴
Radiumhospitalet, Oslo University Hospital PB, Oslo, Norway
🇺🇸
Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, Wisconsin, United States

and more 10 locations

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Phase 2

Terminated

Conditions: Triple Negative Breast Cancer
Inflammatory Breast Cancer Stage IV

Interventions: Drug: Bemcentinib; pembrolizumab

First Posted Date: 2017-06-12

Last Posted Date: 2021-11-09

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 29

Registration Number: NCT03184558

Locations: 🇳🇴
Haukeland University Hospital, Bergen, Norway
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
🇪🇸
Hospital Universitario Germans Trias i Pujol - Institut Catala d'Oncologia, Barcelona, Spain

and more 14 locations

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Bemcentinib
Drug: Cytarabine
Drug: Decitabine

First Posted Date: 2015-07-02

Last Posted Date: 2024-12-19

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 122

Registration Number: NCT02488408

Locations: 🇩🇪
Universitätsklinikum Ulm, Ulm, Germany
🇮🇹
Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
🇩🇪
Medizinische Hochschule Hannover,Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation,, Hannover, Carl-Neuberg-Str, Germany

and more 9 locations

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bemcentinib
Drug: Erlotinib

First Posted Date: 2015-04-23

Last Posted Date: 2025-02-26

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 40

Registration Number: NCT02424617

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 7 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy